Semax vs Selank
Semax is more directly discussed in attention/memory research; Selank has human anxiety-spectrum studies with some reported nootropic effects. Outcomes are not interchangeable.
| Attribute | Semax | Selank |
|---|---|---|
| Human evidence | Older regional stroke and rehabilitation studies report neurological/functional signals and BDNF changes, but this evidence does not establish healthy-person cognitive enhancement. | Older regional comparative studies report anxiolytic signals in generalized anxiety and related disorders, but modern large placebo-controlled independent replication is sparse. |
| Research focus | Stroke/neuroprotection and cognitive research | Anxiety/stress and neurocognitive research |
| Regulatory status | Not FDA/EMA-approved; US compounding status has been under FDA review. | Not FDA/EMA-approved; FDA highlights limited safety information for compounded use. |
| Route / formulation | Do not convert regional clinical use into a general cognitive-enhancement claim. | Regional intranasal studies do not establish universal product equivalence or long-term safety. |
Why these are compared
These compounds appear in the cognition / stress evidence landscape, but they are not interchangeable. Semax is acth(4-7)-derived synthetic peptide analogue studied in stroke/neuroprotection and cognitive research; Selank is synthetic tuftsin-derived heptapeptide studied in anxiety/stress and neurocognitive research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Semax: Limited/regional human stroke evidence; no established healthy nootropic efficacy.
Selank: Limited/regional human anxiety evidence; contemporary safety certainty limited.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No robust head-to-head trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.